Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.63 |
| ▸ | BCHE | P06276 | 6/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550221 | 1.00 | ACHE (0.63) | ACHEBCHEFAAHABCC4CACNA1F | |
| Hydrochloric Acid SCHEMBL4833887 | 0.99 | ACHE (0.61) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL28409784 | 0.99 | ACHE (0.61) | ACHEBCHEFAAHABCC4CACNA1F | |
| Acetic Acid SCHEMBL27493902 | 0.94 | ACHE (0.60) | ACHEBCHEFAAHABCC4CACNA1F | |
| Acetic Acid SCHEMBL29374009 | 0.94 | ACHE (0.60) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL13317859 | 0.91 | ACHE (0.54) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL14156625 | 0.91 | ACHE (0.54) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL4198622 | 0.87 | ACHE (0.56) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL14215561 | 0.86 | ACHE (0.80) | ACHEBCHEFAAHABCC4CACNA1F | |
| SCHEMBL5442562 | 0.85 | ACHE (0.61) | ACHEBCHEFAAHABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120117949-A | Method for directly preparing tertiary amine compound from aromatic aldehyde, ketone and secondary amine | 湖南大学 | 2025-06-10 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265524-A | Compositions containing mixtures of indene or indane derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| EP-1966136-B1 | NOVEL PROCESS FOR PRODUCTION OF HIGHLY PURE POLYMORPH (I) DONEPEZIL HYDROCHLORIDE | RICHTER GEDEON NYRT (HU) | 2014-02-26 | — | — | EP | claimed |
| US-20100105916-A1 | Processes for Preparing Donepezil | Sterling Biotech Limited (IN) | 2010-04-29 | — | — | US | claimed |
| EP-1773339-A4 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | REDDYS LAB LTD DR (IN) | 2009-07-29 | — | — | EP | claimed |
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | RICHTER GEDEON NYRT. (HU) | 2008-12-11 | — | — | US | claimed |
| US-7446203-B2 | Preparation of intermediates for acetycholinesterase inhibitors | HETERO DRUGS LIMITED (IN) | 2008-11-04 | — | — | US | claimed |
| EP-1966136-A2 | NOVEL PROCESS FOR PRODUCTION OF HIGHLY PURE POLYMORPH (I) DONEPEZIL HYDROCHLORIDE | Richter Gedeon NYRT (HU) | 2008-09-10 | — | — | EP | claimed |
| US-20080114173-A1 | Crystalline Form of Donepezil Hydrochloride | DR. REDDY'S LABORATORIES, INC. | 2008-05-15 | — | — | US | claimed |
| EP-1773339-A2 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2007-04-18 | — | — | EP | claimed |
| EP-1531151-B1 | A process for the preparation of 1-benzyl-4-¬(5,6-dimethoxy-1-indanon)-2-yl| methyl piperidine hydrochloride (donepezil hcl) | USV LTD (IN) | 2007-03-07 | — | — | EP | claimed |
| US-7148354-B2 | Process for preparation of donepezil | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-12-12 | — | — | US | claimed |
| EP-1654230-A1 | PREPARATION OF INTERMEDIATES FOR ACETYL CHOLINESTERASE INHIBITORS | Hetero Drugs Limited (IN) | 2006-05-10 | — | — | EP | claimed |
| US-20060041140-A1 | 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone is hydrogenated using platinum oxide catalyst in the presence of hydrochloric acid under a pressure of 2 bars to give 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride | HETERO DRUGS LIMITED (IN) | 2006-02-23 | — | — | US | claimed |
| WO-2006015338-A2 | CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-02-09 | — | — | WO | claimed |
| EP-1531151-A1 | A process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine hydrochloride (donepezil hcl) | USV Limited (IN) | 2005-05-18 | — | — | EP | claimed |
| WO-2005003092-A1 | PREPARATION OF INTERMEDIATES FOR ACETYL CHOLINESTERASE INHIBITORS | HETERO DRUGS LIMITED (IN) | 2005-01-13 | — | — | WO | claimed |
| US-20040143121-A1 | Process for preparation of donepezil | DR. REDDY'S LABORATORIES LIMITED | 2004-07-22 | — | — | US | claimed |
| US-6649765-B1 | Hydrogenating 5,6-Dimethoxy-2-(pyridin-4-yl)methylene indan-1-one in the presence of catalysts, then alkylating with benzyl bromide, to form drugs used for prophylaxis of nervous system disorders; by product inhibition | USV LIMITED, BSD MARG. (IN) | 2003-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | DRD4, IDO1, ADH1A | ACHE 71/4885BCHE 20/4885FAAH 1333/4885 |
| US-20080114173-A1 | Crystalline Form of Donepezil Hydrochloride | PSEN1, H1-5, BCHE | ACHE 4/4885BCHE 3/4885FAAH 1239/4885 |
| US-20060041140-A1 | 5,6-dimethoxy-2-(4-pyridyl)methyl-1-indanone is hydrogenated using platinum oxide catalyst in the presence of hydrochloric acid under a pressure of 2 bars to give 4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride | ACHE, IDH2, IMPDH2 | ACHE 1/4885BCHE 12/4885FAAH 3009/4885 |
| US-20040143121-A1 | Process for preparation of donepezil | ACHE, ADH1C, COMT | ACHE 1/4885BCHE 16/4885FAAH 1191/4885 |
| US-20100105916-A1 | Processes for Preparing Donepezil | HNMT, PNMT, PSEN1 | ACHE 4/4885BCHE 29/4885FAAH 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.